Early phase clinical trials can be complicated and time-consuming, with their success dependent on several different factors. The outcome of these early phase clinical trials will determine the future of your drug development project, and so ensuring safety and efficiency at every step since the start is vital for its overall success. The clinical operations […]
By Anke van Engen, senior principal, EMEA value & payer evidence, IQVIA, and Dima Samaha, senior principal, EMEA value & payer evidence, IQVIA The European Union (EU) comprises 27 member states (MS) with varying laws, processes and regulatory standards. This variation has led to a complex data landscape for health technologies and drug therapeutics developers, […]
By Axel Hagel, practice leader, PV & RM services, IQVIA Life science data, especially safety data, is exploding. It is estimated that pharmaceutical data is increasing at a rate of 36% annually. This is more than other data-driven industries including finance (26% YoY) and manufacturing (30% YoY). This increase is in part due to digital […]
The question of whether to partner with another company is critical to the long-term development of a biotech. Nonetheless, it can be easy for a small company to underestimate the resources it needs to put into a successful collaboration. Here, we’ll go over some expert advice on what to do and what not to do […]
In the life sciences industry, collaboration is paramount in the field of research, to help move ideas and programs forward through the various stages. Here, experts explain the importance of research collaboration for biotechs. Collaboration in research is critical for the long-term success of biotechs, and going it alone is rarely a feasible option, particularly […]
By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma expertise and infrastructure, which significantly […]